{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T05:27:08Z","timestamp":1709098028755},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,9,15]]},"DOI":"10.2169\/internalmedicine.4787-20","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T22:09:20Z","timestamp":1591654160000},"page":"2255-2260","source":"Crossref","is-referenced-by-count":3,"title":["Methotrexate-associated Lymphoproliferative Disorder in the Liver Resembling Hepatocellular Carcinoma Treated with Transarterial Chemoembolization"],"prefix":"10.2169","volume":"59","author":[{"given":"Mio","family":"Tsuruoka","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Inoue","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Kakazu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Ninomiya","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Iwata","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akitoshi","family":"Sano","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Masamune","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kameda H, Fujii T, Nakajima A, et al. Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol 29: 31-40, 2019.","DOI":"10.1080\/14397595.2018.1472358"},{"key":"2","unstructured":"2. Harigai M. Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: a review of the literature and current perspective. Mod Rheumatol 28: 1-8, 2018."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Saito S, Takeuchi T. Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients. J Clin Exp Hematop 59: 145-155, 2019.","DOI":"10.3960\/jslrt.19028"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54: 692-701, 2006.","DOI":"10.1002\/art.21675"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hashimoto A, Chiba N, Tsuno H, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol 42: 564-571, 2015.","DOI":"10.3899\/jrheum.140533"},{"key":"6","unstructured":"6. Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 328: 1317-1321, 1993."},{"key":"7","unstructured":"7. Gaulard P, Swerdlow S, Harris N, Jaffe E, Sundstrom C. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Swerdlow S, Harris N, Jaffe E, Pileri S, Stein H, Eds. IARC Press, Lyon, 2008: 350-351."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Niitsu N, Okamoto M, Nakamine H, Hirano M. Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. Cancer Sci 101: 1309-1313, 2010.","DOI":"10.1111\/j.1349-7006.2010.01517.x"},{"key":"9","unstructured":"9. Inui Y, Matsuoka H, Yakushijin K, et al. Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal. Leuk Lymphoma 56: 3045-3051, 2015."},{"key":"10","unstructured":"10. Mizusawa T, Kamimura K, Sato H, et al. Methotrexate-related lymphoproliferative disorders in the liver: case presentation and mini-review. World J Clin Cases 7: 3553-3561, 2019."},{"key":"11","unstructured":"11. Ono R, Kumagae T, Uojima H, et al. Hepatic methotrexate-associated lymphoproliferative disorders identified by multiple liver tumors: a case report and review of the literature. J Med Case Rep 13: 196, 2019."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ishii M, Gama H, Chida N, et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 95: 1036-1040, 2000.","DOI":"10.1111\/j.1572-0241.2000.01978.x"},{"key":"13","unstructured":"13. Li C, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus alpha-fetoprotein for hepatocellular carcinoma: a systematic review. Hepatol Res 44: E11-E25, 2014."},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Bruix J, Sherman M; American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022, 2011.","DOI":"10.1002\/hep.24199"},{"key":"15","unstructured":"15. Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 29: 339-364, 2011."},{"key":"16","unstructured":"16. Ellman MH, Hurwitz H, Thomas C, Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol 18: 1741-1743, 1991."},{"key":"17","unstructured":"17. Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 34: 322-331, 2007."},{"key":"18","unstructured":"18. Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol 91: 20-28, 2013."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kameda T, Dobashi H, Miyatake N, et al. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 66: 1302-1309, 2014.","DOI":"10.1002\/acr.22306"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99: 3909-3915, 2002.","DOI":"10.1182\/blood.V99.11.3909"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 14: 1943-1949, 1996.","DOI":"10.1200\/JCO.1996.14.6.1943"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Yamakawa N, Fujimoto M, Kawabata D, et al. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol 41: 293-299, 2014.","DOI":"10.3899\/jrheum.130270"},{"key":"23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1186\/s12885-016-2672-8","volume":"16","author":"S Watanabe","year":"2016","unstructured":"23. Watanabe S, Manabe O, Hirata K, et al. The usefulness of (18) F-FDG PET\/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD). BMC Cancer 16: 635, 2016.","journal-title":"BMC Cancer","ISSN":"http:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"24","unstructured":"24. Watanabe S, Takahashi K, Funakoshi K, Terai S. Methotrexate-associated lymphoproliferative disorder: a rare case of large liver tumors. Hepatology 70: 748-750, 2019."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/18\/59_4787-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T03:44:46Z","timestamp":1600487086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/18\/59_4787-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":24,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4787-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,15]]}}}